Corrigendum to "The Bromodomain and Extraterminal Protein Inhibitor Apabetalone Ameliorates Kidney Injury in Diabetes by Regulating Cholesterol Accumulation and Modulating the Gut Microbiota" [Volume 10, Issue 2, February 2025, Pages 522-534].
「更正啟事：'Bromodomain and Extraterminal Protein Inhibitor Apabetalone 透過調節膽固醇累積及腸道菌相，改善糖尿病腎損傷'【第10卷，第2期，2025年2月，522-534頁】」
Kidney Int Rep 2025-06-09
Corrigendum to "WCN24-1267 EMPAGLIFLOZIN IMPROVES VITALITY AND PROTECT FROM ADVANCED GLYCATION END PRODUCTS IN ENDOTHELIAL CELLS" [<i>Kidney International Reports</i> Volume 9, Issue 4, Supplement, April 2024, Page S637].
對於「WCN24-1267 EMPAGLIFLOZIN 改善活力並保護內皮細胞免受高級糖化終產物的影響」的更正 [<i>Kidney International Reports</i> 第9卷，第4期，補充，2024年4月，第S637頁]。
Kidney Int Rep 2024-07-31
Corrigendum to "Renal Disease in Metabolic Syndrome: the Hidden Role of Intrarenal Ischemia" [<i>Kidney International Reports</i> Volume 9, Issue 5, May 2024, Pages 1419-1428].
對於「Renal Disease in Metabolic Syndrome: the Hidden Role of Intrarenal Ischemia」的更正 [<i>Kidney International Reports</i> 第9卷，第5期，2024年5月，頁1419-1428]。
Kidney Int Rep 2025-02-24
The Bromodomain and Extraterminal Protein Inhibitor Apabetalone Ameliorates Kidney Injury in Diabetes by Regulating Cholesterol Accumulation and Modulating the Gut Microbiota.
Bromodomain 和 Extraterminal 蛋白抑制劑 Apabetalone 透過調節膽固醇積累和調節腸道微生物群來改善糖尿病引起的腎損傷。
Kidney Int Rep 2025-02-24
Corrigendum to "WCN25-3808 NAFLD IN ESRD - PREVALENCE OF NAFLD in ESRD PATIENTS AND EVALUATION OF THERAPEUTIC EFFICACY OF TOCOTRIENOL IN TREATMENT OF NAFLD" [<i>Kidney International Reports</i> Volume 10, Issue 2, Supplement, February 2025, Pages S339-S340].
更正啟事：「WCN25-3808 末期腎臟病（ESRD）中的非酒精性脂肪肝病（NAFLD）—ESRD 患者中 NAFLD 的盛行率及 tocotrienol 治療 NAFLD 療效之評估」[《Kidney International Reports》2025年2月，第10卷，第2期，增刊，S339-S340頁]
Kidney Int Rep 2025-04-30
Erratum to "Anticoagulation for the Prevention of Thrombotic Events in Nephrotic Syndrome" [<i>Kidney International Reports</i> Volume 9, Issue 10, October 2024, Pages 3053-3056].
「『Anticoagulation for the Prevention of Thrombotic Events in Nephrotic Syndrome』一文的勘誤啟事」
Kidney Int Rep 2025-04-30
Corrigendum to "Study Design and Baseline Characteristics of ALIGN, a Randomized Controlled Study of Atrasentan in Patients With IgA Nephropathy" [Volume 10, Issue 1, January 2025, Pages 217-226].
更正啟事：「ALIGN 隨機對照研究 Atrasentan 用於 IgA Nephropathy 患者之研究設計與基線特徵」[第10卷，第1期，2025年1月，頁217-226]
Kidney Int Rep 2025-04-30
重點摘要：
這則通知是用來更正 DOI 為 10.1016/j.ekir.2024.10.004 的文章。內容很可能是針對該篇發表的錯誤進行修正，或是提供相關的最新更新。
PubMedDOI
Corrigendum to "PREGNANCY AS A WINDOW TO CURRENT AND FUTURE KIDNEY HEALTH-AN OPPORTUNITY" [Volume 10, Issue 3, March 2025, Pages 645-649].
「PREGNANCY AS A WINDOW TO CURRENT AND FUTURE KIDNEY HEALTH-AN OPPORTUNITY」[第10卷，第3期，2025年3月，第645-649頁]之更正啟事
Kidney Int Rep 2025-06-09
Corrigendum to "SAT-040 RENAL SAFETY OF DIRECT ACTING ANTIVIRAL DRUGS IN POST LIVER TRANSPLANT PATIENTS WITH CHRONIC HEPATITIS C VIRUS INFECTION" [Volume 5, Issue 3, Supplement, March 2020, Pages S18-S19].
「SAT-040 直接作用型抗病毒藥物於肝臟移植後慢性 C 型肝炎患者之腎臟安全性」更正啟事 [第5卷，第3期，增刊，2020年3月，S18-S19頁]
Kidney Int Rep 2025-06-09